International Alliance for Personalised Medicine, shared on LinkedIn:
“Some conversations are too important to miss.
During United Nations General Assembly High-Level Week in New York, the International Alliance for Personalised Medicine will convene senior leaders from healthcare, science, industry and policy to examine a defining question:
- How do we turn molecular data into better decisions, and better outcomes, for patients?
We are honoured to welcome Helmy Eltoukhy, PhD, Co-Founder, Chairman and Co-Chief Executive Officer of Guardant Health.
From pioneering semiconductor sequencing to co-founding Guardant Health with Dr. AmirAli Talasaz, Dr. Eltoukhy has helped shape the development of liquid biopsy and data-driven precision oncology. Guardant’s work has advanced the use of blood-based molecular information to support cancer detection, treatment selection and disease monitoring.
His perspective will bring exceptional insight to our discussion on how innovation moves from scientific breakthrough to clinical adoption, policy support and patient access.
Together with Guardant Health, we will explore how AI, diagnostics and health-system readiness can ensure that increasingly sophisticated data translates into timely, meaningful care.
This will be a high-level exchange at the centre of the global healthcare agenda.”
New York | 23 September 2026
